INTRODUCTION
The relationship between cytokines and vitreoretinal diseases has been widely examined. 1 In particular, increased vitreous levels of cytokines, such as platelet-derived growth factor (PDGF), transforming growth factor-b (TGFb), tumour necrosis factor-a (TNFa) and interleukin-1b (IL-1b) have been shown to cause vitreoretinal diseases. 2e4 Among many factors promoting vitreoretinal diseases, TNFa is known to be one of the key regulators that are intimately involved in the pathogenesis of uveitis and intraocular angiogenic diseases such as diabetic retinopathy 5 and agerelated macular degeneration. 6 TNFa is a proinflammatory cytokine produced by activated monocytes, glial cells 7 and retinal pigment epithelium (RPE). 8 TNFa also acts as an angiogenic and permeability factor in various mechanisms. 9 Recently, drugs that target TNFa have been used in patients with ocular inflammation. 10 Hyalocytes have been described as occurring in the peripheral or cortical region of the vitreous close to the inner surface of the retina. 11 Although hyalocytes were discovered more than a 100 years ago, the molecular and cellular biological characteristics of hyalocytes have yet to be fully elucidated. 12 We have reported that hyalocytes are resident macrophages and originate from the blood monocytes. 13 Hyalocytes have rare mitotic activity under physiological conditions. 14 However, under pathological conditions our studies demonstrated that hyalocytes play important roles in the pathogenesis of proliferative vitreoretinal diseases and that they are a candidate for cellular targeting therapy.
2 15e17 PDGF-BB or TGFb induced proliferation of hyalocytes and gel contraction in an in vitro wound-healing assay embedding hyalocytes. 2 3 18 However, it is not known how hyalocytes contribute to inflammatory proliferative vitreoretinal diseases.
Steroids have been used for the treatment of ocular inflammation. Intravitreal injection of steroids is currently used in the management of intravitreal inflammation in various vitreoretinal diseases, including uveitis and diabetic retinopathy. 19 20 Recently, we have shown that vascular epithelial growth factor (VEGF)-A expression by hyalocytes is inhibited by dexamethasone. 21 However, the effects of dexamethasone on the functional properties of hyalocytes in inflammationassociated diseases have not been clarified.
In this study, to reveal the possible role of hyalocytes in inflammatory vitreoretinal diseases, we investigated the impact of TNFa on the properties of hyalocytes and the effects of steroids on hyalocytes under TNFa stimulation.
MATERIALS AND METHODS Materials
Recombinant human TNFa (T6674), TGFb2 (T2815) and dexamethasone (D2915) were obtained from Sigma-Aldrich (St Louis, Missouri, USA). Recombinant human VEGF-A165 (293-VE) and monocyte chemoattractant protein 1 (MCP-1) (279-MC) were obtained from R&D Systems (Minneapolis, Minnesota, USA).
Cell isolation and identification
Bovine hyalocytes were isolated and cultivated as previously reported. 3 Hyalocytes obtained between passages 4 and 7 were used in experiments.
[ 3 H]-Thymidine uptake
The hyalocytes were seeded into 24-well plates at a density of 1310 4 cells/well. After 24 h starvation, the cells were stimulated with each cytokine for 18 h. 
Chemotaxis assay
The assay was performed using a 24-well Boyden's chemotaxis chamber (Chemotaxicell (Cosmo Bio, Tokyo, Japan); 8 mm pores) with a slight modification to the previously described method. 9 After incubation for 4 h at 378C, the migrated cells were observed. Three random objective fields of stained cells were counted for each well, and the mean number of migrating cells per one field was calculated. The number of migrated cells, obtained from six independent wells for each group, was compared using analysis of variance (ANOVA) and Dunnett's tests.
Collagen gel contraction
The contraction assay was performed as previously described. 22 Bovine hyalocytes were collected by treatment of cultures with trypsin-EDTA for 3 min, washed with unsupplemented minimal essential medium (MEM), and resuspended in MEM at a density of 2.2310 6 cells/ml. Type I collagen (Koken Co, Tokyo, Japan), reconstitution buffer, hyalocyte suspension and water were mixed on ice at a ratio of 7:1:1:1 (final concentration of type I collagen gel, 1.9 mg/ml; final cell density, 2310 5 cells/ml). The resultant mixture (0.5 ml) was added to a 24-multiwell plate (Nunc, Roskilde, Denmark), and the formation of collagen gels induced by incubation at 378C under 5% CO 2 for 60 min). After gelatinisation, 0.5 ml Dulbecco's modified Eagle's medium was added to each well. The gels were then freed from the walls of the culture wells with a microspatula. The diameter of the collagen gel was measured with a ruler 48 h after stimulation. For quantitative purposes, contraction data are presented as the change in diameter.
Western blot analysis
Cell lysates were separated on sodium dodecyl sulfate/polyacrylamide gels and transferred to nitrocellulose membranes. The blots were incubated overnight at 48C with anti-phospho-p44/42 mAb (1:1000, #9106; Cell Signaling Technology, Beverly, California, USA) or p44/42 (1:200, SC-94; Santa Cruz, California, USA).
Statistical analysis
The experimental data are expressed as mean6SD. Statistical significance was assumed when p was <0.05 using the Student t test in normally distributed populations. figure 1A) . Furthermore TNFa showed the mitogenic activity in a dose-dependent manner (figure 1B). To investigate if a potent steroid, dexamethasone, inhibited TNFa-induced thymidine uptake by hyalocytes, we treated TNFa-stimulated hyalocytes with dexamethasone. Dexamethasone (1 nM) inhibited TNFa-induced thymidine uptake significantly ( figure 1C ). These data indicate that TNFa causes hyalocytes to proliferate and that dexamethasone inhibits the proliferation.
RESULTS

Effect of TNFa on mitogenic activity of hyalocytes
Effect of TNFa on hyalocyte migration
To further explore the effect of TNFa, VEGF-A or MCP-1 on the properties of hyalocytes, we examined hyalocyte migration with or without TNFa, VEGF-A or MCP-1 stimulation. The Boyden chamber showed that all these cytokines induce hyalocyte migration significantly (figure 2A). While TNFa caused significant hyalocyte migration, dexamethasone did not inhibit TNFainduced migration by hyalocytes ( figure 2B ). Dexamethasone neither inhibited VEGF-A-nor MCP-1-induced migration by hyalocytes (data not shown). 
Effect of TNFa on collagen gel contraction by hyalocytes
To examine the effect of TNFa, VEGF-A or MCP-1 on gel contraction, we used in vitro gel contraction. As shown previously, TGFb caused significant collagen gel contraction ( figure 3A,B) . TNFa also induced significant collagen gel contraction by hyalocytes ( figure 3A,B) , whereas neither VEGF-A nor MCP-1 affected the collagen gel contraction (data not shown). To examine the effect of dexamethasone on TNFaor TGFb-induced collagen gel contraction by hyalocytes, we treated hyalocytes with 100 nM dexamethasone. Interestingly, dexamethasone enhanced untreated or TNFa-or TGFb-induced collagen gel contraction by hyalocytes ( figure 3A,B) . This observation indicates that dexamethasone causes gel contraction with hyalocytes in both non-inflammatory and inflammatory states.
Effect of dexamethasone on TNFa-induced signalling in hyalocytes
To investigate the mechanism of TNFa-induced hyalocytes properties, we examined extracellular signal-related kinase (ERK) 1/2 in hyalocytes (ERK1/2 is important for cell proliferation and migration). Western blotting showed that ERK1/2 was phosphorylated 15 min after TNFa stimulation in hyalocytes ( figure 4A ). Furthermore we confirmed that dexamethasone inhibited TNFa-induced phosphorylation in hyalocytes (figure 4B). These data indicate ERK1/2-regulated hyalocytes properties under conditions of TNFa stimulation.
DISCUSSION
Our previous studies have shown that TGFb and PDGF regulate the functional properties of hyalocytes and that phenotype switching contributes to various vitreoretinal diseases. We have Figure 2 Tumour necrosis factor-a (TNFa)-induced hyalocyte migration and the effect of dexamethasone. (A) Hyalocyte migration with Boyden chamber in the presence of TNFa (10 ng/ml), vascular endothelial growth factor (VEGF)-A (10 ng/ml) or monocyte chemoattractant protein 1 (MCP-1) (10 ng/ml) for 4 h (n¼6). (B) Hyalocyte migration in the presence of TNFa (10 ng/ml) with or without dexamethasone (100 nM) for 4 h (n¼12). *p<0.05; **p<0.01. 
Laboratory science
shown that TGFb induces gel contraction by hyalocytes. 2 18 PDGF, which is an important modulator in vitreoretinal diseases, also affects gel contraction by hyalocytes. 3 The present study shows that TNFa also induces slight but significant hyalocytemediated gel contraction. Furthermore, TNFa as well as PDGF induces proliferation and migration of hyalocytes, whereas TGFb inhibits hyalocyte proliferation (data not shown). This indicates that each cytokine has a different effect on hyalocytes. Furthermore, the other cytokines might affect or be affected by TNFa expression or activity and make the progression of vitreoretinal disease complex. Several studies have reported TNFa upregulation in vitreoretinal diseases. 4 Hyalocytes are activated by TNFa and contribute to the pathogenesis of the vitreoretinal diseases. Pars plana vitrectomy is reported to be useful in improving vision, reducing disease activity or ameliorating cystoid macular oedema in patients with uveitis 23 or diabetic retinopathy. Removal of TNFa and/or activated hyalocytes by vitrectomy might be one of the factors contributing to the reduction of disease activity. Recent successful outcome of antiTNFa therapy might also be attributed to the inhibitory effect on the activity of hyalocytes.
In our recent study, not only glial cells but also hyalocytes were observed in epiretinal membranes from patients. 15 It has been reported that TNFa is expressed in epiretinal membranes in various retinal diseases. 5 TNFa upregulation promotes the formation of epiretinal membrane with hyalocyte activation (figure 5). Epiretinal membranes are often observed in eyes with uveitis, and the posterior vitreous thickens and behaves like an epiretinal membrane in eyes with diabetic retinopathy. 24 Antiinflammatory therapy targeting activated hyalocytes might thus prevent the formation of epiretinal membrane under these pathological conditions (figure 5).
Dexamethasone inhibits VEGF-A expression by hyalocytes. 21 In this study, we observed that dexamethasone inhibited TNFainduced proliferation of hyalocytes but not migration ( figure 5 ).
Furthermore, TNFa-induced ERK1/2 phosphorylation was inhibited by dexamethasone treatment in hyalocytes, suggesting that ERK1/2 activation in hyalocytes must be important for proliferation but not migration. Unexpectedly, dexamethasone enhanced collagen gel contraction not only in TNFa stimulation, but also in the unstimulated state. Once the epiretinal membrane is formed, intravitreal injection of steroid might cause membrane contraction with or without tractional retinal detachment in patients with proliferative vitreoretinal diseases. We have to be careful of the adverse effects of steroid treatment in eyes with such pathological conditions. In such cases, steroid combination therapy with an anti-contraction drug might help to prevent membrane contraction while reducing inflammation ( figure 5 ).
We have shown that hyalocytes are an important component in the pathogenesis of vitreoretinal diseases in conjunction with several cytokines. Each cytokine has shown differential effects on the functional properties of hyalocytes. Further understanding of the effects of cytokines on hyalocytes will help the development of novel therapies for vitreoretinal disorders. Figure 5 Tumour necrosis factor-a (TNFa)-induced hyalocyte activation and the impact of steroid treatment. Various retinal disorders (uveitis, diabetic retinopathy, photocoagulation or surgery, etc.) cause TNFa upregulation in vitreous or retina. TNFa can activate resting hyalocytes and induce hyalocyte migration and proliferation on the vitreoretinal interface. Activated hyalocytes contribute to the membrane formation on vitreoretinal interface. Steroid treatment can inhibit the proliferation and probably the membrane formation. TNFa as well as transforming growth factor-b (TGFb) 17 18 causes membrane contraction. However, once the membrane has formed, steroid treatment can reverse membrane contraction.
